Barclays
DNTH icon

Barclays’s Dianthus Therapeutics DNTH Stock Holding History

Barclays’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.39M Buy
+83,900
New +$8.71M ﹤0.01% 1829

Other funds holding DNTH

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Barclays's DNTH Position: Q3 2026 in Review

Barclays increased its Dianthus Therapeutics (DNTH) stake by 1.7% in Q3 2026, buying an estimated $781K and bringing the position to 439,276 shares worth $38.7M. The position accounts for 0.01% of the portfolio, ranked #898.

Barclays first reported a position in DNTH in Q3 2018 and has held it in 32 quarters since. The position peaked at $42.1M in Q2 2026. 77 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • Barclays held 439,276 shares of Dianthus Therapeutics worth $38.7M as of Q3 2026.
  • Barclays bought 7,523 Dianthus Therapeutics shares in Q3 2026, an estimated $781K.
  • Dianthus Therapeutics made up 0.01% of Barclays's portfolio in Q3 2026, its #898 holding.
  • Barclays first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 32 quarters since.
  • Barclays's Dianthus Therapeutics position peaked at $42.1M in Q2 2026.
  • 77 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.